Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

	E	uyai riii	iy. 00			FEU	103 10	IC - F0IIII 4			
CORCEPT Form 4 April 05, 20	THERAPEUTICS	5 INC									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							-	3235-0287			
Check this box if no longer subject to Section 16. SECURITIES SECURITIES LABOR SECURITIES L									urs per		
(Print or Type	Responses)										
BELANOFF JOSEPH K Symbol				er Name an EPT THE			-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Mont			(Month/I	Date of Earliest Transaction onth/Day/Year) 03/2006				X DirectorX 10% Owner X Officer (give title Other (specify below) below) Chief Executive Officer			
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)						 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 					
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	e Secu	rities Acq	uired, Disposed of	f, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			
Common Stock	04/03/2006			S <u>(1)</u>	2,452	D	\$ 5.0761	2,241,743	D		
Common Stock								300,000	I	Custodian for minor son (2)	
Common Stock								300,000	I	Custodian for a minor daughter $\frac{(2)}{2}$	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

-

Reporting Owners

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Under Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
BELANOFF JOSEPH K C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025	Х	Х	Chief Executive Officer					

Signatures

s/s Fred Kurland, CFO of Corcept Therapeutics Incorporated attorney-in-fact 04/05/2006 <u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004.
- (2) The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.